StockWatch
·

Nureca Ltd Q2 FY27 Results

NURECAQ2 FY27 Results
Filing
Result:Steady· Market: Up#Margin squeeze#Record quarter
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue58.5345.1%55.1%
Total Income59.8842.0%49.5%
Expenditure54.3644.1%53.3%
PBT5.5224.4%20.0%
Net Profit4.0532.1%11.7%
OPM8.93%0.26pp
NPM6.77%0.50pp2.29pp
EPS4.2532.4%17.1%
View full financials

Revenue grew a strong 55% YoY but adjusted PAT growth of only 11.7% reflects a product-cost-led margin squeeze (NPM down to 6.77% from 9.06%), making this an in-line quarter despite the record absolute PAT.

Q2 FY-2027 RESULTS · NURECA

Nureca Q2 FY27: revenue up 55% YoY, margin compression caps PAT growth at 12%

PAT +11.7% YoY · revenue +55.1% · margins compressing

21 Oct 2026 · 3 min read
Revenue

₹58.53 Cr

+55.1% YoY

PAT (consolidated)

₹4.05 Cr

+11.7% YoY

Net margin

6.77%

-2.3pp YoY

EPS

₹4.25

Nureca's consolidated (primary) revenue for Q2 FY27 came in at ₹58.53 Cr, up 55.1% YoY from ₹37.74 Cr and up 45.1% QoQ from ₹40.34 Cr — a sharp acceleration in the home-healthcare products business. But consolidated PAT from continuing operations grew only 11.7% YoY to ₹4.05 Cr (₹3.63 Cr a year ago), even as it jumped 32.1% QoQ (₹3.07 Cr) — the QoQ pop is not the headline because YoY profit growth trails YoY revenue growth by a wide margin. Net profit margin compressed to 6.77% from 9.06% a year ago and 7.27% last quarter. No analyst consensus or brokerage preview could be found for this print — coverage is effectively absent for a company this size — so vs-street is unknown; management has also issued no formal guidance on record, so vs-guidance is unknown too.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹58.53 Cr+45.1%+55.1%
Expenses₹54.36 Cr+44.1%+53.3%
PAT₹4.05 Cr+32.1%+11.7%
Net margin6.77%-0.5pp-2.3pp
EPS₹4.25+32.4%+17.1%

The margin squeeze sits on the cost-of-goods line: net of the inventory build, material-related costs (purchase of stock-in-trade less the change in inventories) rose roughly 81% YoY, well ahead of the 55% revenue growth, while employee costs were nearly flat YoY (₹4.11 Cr vs ₹4.17 Cr) and finance costs fell (₹0.26 Cr vs ₹0.46 Cr), so the pressure is specifically a product-cost/mix issue rather than a cost-structure one. Depreciation rose to ₹0.81 Cr from ₹0.54 Cr as the company ramped capex — H1 cash outflow for property, plant, equipment and intangibles was ₹21.40 Cr, with a new ₹5.34 Cr capital-work-in-progress balance appearing on the books, consistent with capacity expansion. Standalone PAT grew a touch faster at 15.4% YoY (₹3.62 Cr vs ₹3.14 Cr) against consolidated's 11.7% — a ~3.7 percentage-point divergence, modest but above the threshold worth flagging; subsidiary-level results (Nureca Technologies, Nureca INC) weighed slightly on the group number without materially changing the picture.

₹
271.21299.08326.95354.82382.69324.907-2008-1109-0209-2510-21Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹324.9, down 6.3% over the past month of trading.

₹ Cr
-7.31-3.121.085.270.81Q1 FY26rev ₹34 Cr3.63Q2 FY26rev ₹38 Cr3.73Q3 FY26rev ₹40 Cr-6.09Q4 FY26rev ₹35 Cr3.07Q1 FY27rev ₹40 Cr4.05Q2 FY27rev ₹59 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters.

On corporate developments, the company closed a DRI (customs) matter this quarter with a ₹0.57 Cr pre-deposit appropriated to settle it — a resolved legal overhang rather than a fresh charge visible as a separate P&L line. Promoter and MD Saurabh Goyal made several open-market purchases through late September and early October 2026, after the trading window closed around the results date — a demonstrated-confidence signal that sits alongside, but is not proof of, the quarter's numbers. No management press release accompanied this filing, so there is no standalone management commentary to cross-check against the print beyond the audited statement and the limited-review auditor's notes, which raised no qualifications.

  • W1

    Whether NPM recovers toward the ~9% YoY-ago level as the revenue surge scales, given this quarter's net material-cost growth (~81% YoY) outpaced revenue growth (55.1% YoY)

  • W2

    Whether the ₹21.40 Cr H1 capex and new ₹5.34 Cr CWIP convert into revenue-generating capacity next quarter, and whether borrowings/finance costs stay contained while funding it

  • W3

    Whether the ₹58.53 Cr quarterly revenue run-rate holds as a new base or proves a one-quarter spike, given Q1 FY27 was only ₹40.34 Cr

Figures converted from ₹ million to ₹ Cr (÷10); source statement is machine-generated and fully legible. Consolidated PAT is from continuing operations (nil from discontinued ops). No line is flagged 'exceptional' in either statement, so adjusted PAT equals reported PAT; the ₹0.57 Cr DRI pre-deposit appropriation is noted as a resolved legal item but not isolated as a P&L exceptional since the filing doesn't call it out as one.

Informational and educational content only. Not investment advice.